Artelo Biosciences, Inc.
ARTL Nasdaq Pharmaceutical Preparations Financials FY2016โFY2025
Last close ยท Oct 23, 2026
$2.55
0.0%
Revenue
Total sales reported in the income statement.
โ
vs prior year
Operating margin
Operating income as a share of revenue.
โ
Net income
Profit after all expenses, interest and tax.
โ$12.9M
Free cash flow
Cash from operations minus capital spending.
โ
Return on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
โ
Market cap
Last close times the latest diluted share count, so it is approximate.
$6.9M
Oct 23 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
0.2x
On $12.00 EPS (TTM)
What Artelo Biosciences, Inc. does
No business description yet.
- Legal name
- ARTELO BIOSCIENCES, INC.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K ยท Feb 24, 2026
- Accession ยท CIK
- 0001640334-26-000368
0001621221
Revenue and margins
Artelo Biosciences, Inc. had โ of revenue in fiscal 2025.
FY16
Revenue โ
FY17
Revenue โ
FY18
Revenue โ
FY19
Revenue โ
FY20
Revenue โ
FY21
Revenue โ
FY22
Revenue โ
FY23
Revenue โ
FY24
Revenue โ
FY25
Revenue โ
FY16
Gross โ
Operating โ
Net โ
FCF โ
FY17
Gross โ
Operating โ
Net โ
FCF โ
FY18
Gross โ
Operating โ
Net โ
FCF โ
FY19
Gross โ
Operating โ
Net โ
FCF โ
FY20
Gross โ
Operating โ
Net โ
FCF โ
FY21
Gross โ
Operating โ
Net โ
FCF โ
FY22
Gross โ
Operating โ
Net โ
FCF โ
FY23
Gross โ
Operating โ
Net โ
FCF โ
FY24
Gross โ
Operating โ
Net โ
FCF โ
FY25
Gross โ
Operating โ
Net โ
FCF โ
Gross
Operating
Net
FCF
Net income and earnings per share
Loss periods are shown in red.
FY16
Net income โ$0.0M
FY17
Net income โ$0.2M
FY18
Net income โ$2.3M
FY19
Net income โ$2.2M
FY20
Net income โ$4.7M
FY21
Net income โ$7.4M
FY22
Net income โ$10.1M
FY23
Net income โ$9.3M
FY24
Net income โ$9.8M
FY25
Net income โ$12.9M
Q3 '23
Net income โ$2.4M
Q4 '23
Net income โ$3.1M
Q1 '24
Net income โ$2.5M
Q2 '24
Net income โ$2.4M
Q3 '24
Net income โ$1.1M
Q4 '24
Net income โ$3.8M
Q1 '25
Net income โ$2.4M
Q2 '25
Net income โ$3.2M
Q3 '25
Net income โ$3.1M
Q4 '25
Net income โ$4.2M
Q1 '26
Net income โ$3.0M
Q2 '26
Net income โ$2.4M
FY16
Diluted EPS $0.00
FY17
Diluted EPS โ$0.03
FY18
Diluted EPS โ$1.84
FY19
Diluted EPS โ$1.46
FY20
Diluted EPS โ$1.26
FY21
Diluted EPS โ$0.40
FY22
Diluted EPS โ
FY23
Diluted EPS โ$3.14
FY24
Diluted EPS โ$18.30
FY25
Diluted EPS โ$12.52
Q3 '23
Diluted EPS โ$0.83
Q4 '23
Diluted EPS โ
Q1 '24
Diluted EPS โ$0.78
Q2 '24
Diluted EPS โ$4.52
Q3 '24
Diluted EPS โ$2.10
Q4 '24
Diluted EPS โ$10.90
Q1 '25
Diluted EPS โ$12.55
Q2 '25
Diluted EPS โ$16.86
Q3 '25
Diluted EPS โ$3.97
Q4 '25
Diluted EPS $20.86
Q1 '26
Diluted EPS โ$4.00
Q2 '26
Diluted EPS โ$0.89
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FY16
Return on capital โ
Return on equity โ
Return on assets โ825.0%
FY17
Return on capital โ
Return on equity โ88.5%
Return on assets โ81.3%
FY18
Return on capital โ
Return on equity โ1,143.7%
Return on assets โ482.5%
FY19
Return on capital โ
Return on equity โ81.6%
Return on assets โ63.1%
FY20
Return on capital โ
Return on equity โ99.7%
Return on assets โ85.7%
FY21
Return on capital โ
Return on equity โ47.9%
Return on assets โ45.6%
FY22
Return on capital โ
Return on equity โ43.3%
Return on assets โ41.4%
FY23
Return on capital โ
Return on equity โ59.6%
Return on assets โ55.5%
FY24
Return on capital โ
Return on equity โ134.5%
Return on assets โ110.8%
FY25
Return on capital โ
Return on equity โ1,625.1%
Return on assets โ343.5%
Return on capital
Return on equity
Return on assets
Cash flow
Free cash flow was โ in fiscal 2025, โ of revenue. Cash from operations minus capital spending.
FY16
Free cash flow โ
FY17
Free cash flow โ
FY18
Free cash flow โ
FY19
Free cash flow โ
FY20
Free cash flow โ
FY21
Free cash flow โ
FY22
Free cash flow โ
FY23
Free cash flow โ
FY24
Free cash flow โ
FY25
Free cash flow โ
FY16
Cash from operations โ$0.0M
Capital spending โ
FY17
Cash from operations โ$0.2M
Capital spending โ
FY18
Cash from operations โ$1.6M
Capital spending โ
FY19
Cash from operations โ$2.8M
Capital spending โ
FY20
Cash from operations โ$4.3M
Capital spending โ
FY21
Cash from operations โ$6.1M
Capital spending โ
FY22
Cash from operations โ$8.0M
Capital spending โ
FY23
Cash from operations โ$8.2M
Capital spending โ
FY24
Cash from operations โ$8.4M
Capital spending โ
FY25
Cash from operations โ$8.5M
Capital spending โ
Cash from operations
Capital spending
Q3 '23
Cash from operations โ$1.8M
Capital spending โ
Q4 '23
Cash from operations โ$2.6M
Capital spending โ
Q1 '24
Cash from operations โ$2.9M
Capital spending โ
Q2 '24
Cash from operations โ$2.1M
Capital spending โ
Q3 '24
Cash from operations โ$0.8M
Capital spending โ
Q4 '24
Cash from operations โ$2.6M
Capital spending โ
Q1 '25
Cash from operations โ$1.6M
Capital spending โ
Q2 '25
Cash from operations โ$0.5M
Capital spending โ
Q3 '25
Cash from operations โ$3.5M
Capital spending โ
Q4 '25
Cash from operations โ$2.9M
Capital spending โ
Q1 '26
Cash from operations โ$1.2M
Capital spending โ
Q2 '26
Cash from operations โ$5.0M
Capital spending โ
Cash from operations
Capital spending
Dividends, buybacks and share count
Artelo Biosciences, Inc. returned โ to shareholders in fiscal 2025. The diluted share count rose 91.6%.
FY16
Dividends โ
Buybacks โ
FY17
Dividends โ
Buybacks โ
FY18
Dividends โ
Buybacks โ
FY19
Dividends โ
Buybacks โ
FY20
Dividends โ
Buybacks โ
FY21
Dividends โ
Buybacks โ
FY22
Dividends โ
Buybacks โ
FY23
Dividends โ
Buybacks โ
FY24
Dividends โ
Buybacks โ
FY25
Dividends โ
Buybacks โ
Dividends
Buybacks
FY16
Diluted shares 0.01B
FY17
Diluted shares 0.00B
FY18
Diluted shares 0.00B
FY19
Diluted shares 0.00B
FY20
Diluted shares 3.71B
FY21
Diluted shares 0.02B
FY22
Diluted shares โ
FY23
Diluted shares 0.00B
FY24
Diluted shares 0.00B
FY25
Diluted shares 0.00B
Balance sheet
Cash, debt and the ratios that show how comfortably Artelo Biosciences, Inc. can carry it.
FY16
Cash $0.0M
Debt โ
FY17
Cash $0.6M
Debt โ
FY18
Cash $0.3M
Debt โ
FY19
Cash $4.4M
Debt โ
FY20
Cash $2.1M
Debt โ
FY21
Cash $24.1M
Debt โ
FY22
Cash $16.0M
Debt โ
FY23
Cash $10.4M
Debt โ
FY24
Cash $2.3M
Debt โ
FY25
Cash $0.6M
Debt โ
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $24.1M | $16.0M | $10.4M | $2.3M | $0.6M |
| Interest coverage | โ | โ2,057.4x | โ | โ | โ58.8x |
| Current ratio | 24.0x | 18.4x | 8.5x | 1.4x | 0.2x |
| Quick ratio | 24.0x | 18.4x | 8.5x | 1.4x | 0.2x |
| Total assets | $28.3M | $20.4M | $13.0M | $4.7M | $2.8M |
| Total liabilities | $1.1M | $1.0M | $1.3M | $1.8M | $4.1M |
| Shareholders' equity | $27.2M | $19.4M | $11.8M | $2.9M | โ$1.3M |
| Net debt (โ = net cash) | โ | โ | โ | โ | โ |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โPlanโ marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
โ
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8โ9 is strong, 0โ2 weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | โ | โ | โ | โ | โ | โ | โ | โ | โ | โ |
| Cash from operations is positive | โ | โ | โ | โ | โ | โ | โ | โ | โ | โ |
| Return on assets rose | โ | โ | โ | โ | โ | โ | โ | โ | โ | โ |
| Cash from operations exceeds net income | โ | โ | โ | โ | โ | โ | โ | โ | โ | โ |
| Debt fell relative to assets | โ | โ | โ | โ | โ | โ | โ | โ | โ | โ |
| Current ratio rose | โ | โ | โ | โ | โ | โ | โ | โ | โ | โ |
| Share count didn't rise | โ | โ | โ | โ | โ | โ | โ | โ | โ | โ |
| Gross margin rose | โ | โ | โ | โ | โ | โ | โ | โ | โ | โ |
| Revenue rose relative to assets | โ | โ | โ | โ | โ | โ | โ | โ | โ | โ |
| F-score | โ / 3 | โ / 6 | โ / 6 | โ / 6 | โ / 6 | โ / 6 | โ / 5 | โ / 5 | โ / 6 | โ / 6 |
| Accruals ratio | โ311.1% | โ6.3% | โ151.0% | 18.0% | โ5.7% | โ7.9% | โ8.5% | โ6.5% | โ16.6% | โ116.3% |
| Altman Z'' | โ135.93 | 21.22 | โ63.84 | 3.32 | โ3.37 | 27.60 | 17.18 | โ0.76 | โ46.52 | โ108.87 |
10 years of figures
Amounts in USD. Hover a ratioโs name for its definition.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Research and development | โ | โ | $1.2M | $1.1M | $1.9M | $2.8M | $4.3M | $5.7M | $6.0M | $5.4M |
| Operating income | โ$0.0M | โ$0.2M | โ$2.3M | โ$3.2M | โ$4.7M | โ$7.4M | โ$10.3M | โ$9.9M | โ$10.1M | โ$11.4M |
| Interest expense | โ | $0.0M | โ | โ | โ | $0.0M | $0.0M | $0.0M | $0.0M | $0.2M |
| Income tax | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Net income | โ$0.0M | โ$0.2M | โ$2.3M | โ$2.2M | โ$4.7M | โ$7.4M | โ$10.1M | โ$9.3M | โ$9.8M | โ$12.9M |
| Diluted EPS | $0.00 | โ$0.03 | โ$1.84 | โ$1.46 | โ$1.26 | โ$0.40 | โ | โ$3.14 | โ$18.30 | โ$12.52 |
| Diluted shares | 0.01B | 0.00B | 0.00B | 0.00B | 3.71B | 0.02B | โ | 0.00B | 0.00B | 0.00B |
| Cash flow | ||||||||||
| Cash from operations | โ$0.0M | โ$0.2M | โ$1.6M | โ$2.8M | โ$4.3M | โ$6.1M | โ$8.0M | โ$8.2M | โ$8.4M | โ$8.5M |
| Depreciation and amortization | โ | โ | $0.0M | $0.0M | $0.0M | โ | โ | โ | โ | โ |
| Stock-based compensation | โ | $0.0M | $0.3M | $0.4M | $0.4M | $1.5M | $2.5M | $1.0M | $0.8M | $1.1M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $0.0M | $0.6M | $0.3M | $4.4M | $2.1M | $24.1M | $16.0M | $10.4M | $2.3M | $0.6M |
| Current assets | $0.0M | $0.6M | $0.4M | $4.4M | $2.3M | $24.6M | $18.3M | $11.0M | $2.6M | $0.7M |
| Current liabilities | $0.0M | $0.0M | $0.5M | $1.0M | $0.5M | $1.0M | $1.0M | $1.3M | $1.8M | $4.0M |
| Property and equipment, net | โ | โ | $0.0M | $0.0M | $0.0M | โ | โ | โ | โ | โ |
| Intangible assets | โ | โ | โ | $2.0M | $2.0M | $2.0M | $2.0M | $2.0M | $2.0M | $2.0M |
| Total assets | $0.0M | $0.6M | $0.4M | $6.5M | $4.4M | $28.3M | $20.4M | $13.0M | $4.7M | $2.8M |
| Total liabilities | $0.0M | $0.0M | $0.5M | $1.0M | $0.5M | $1.1M | $1.0M | $1.3M | $1.8M | $4.1M |
| Preferred stock | โ | โ | โ | โ | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | โ$0.0M | $0.5M | โ$0.1M | $5.5M | $3.9M | $27.2M | $19.4M | $11.8M | $2.9M | โ$1.3M |
| Returns | ||||||||||
| Return on capital employed | 215.2% | โ42.7% | 1,735.9% | โ58.8% | โ120.9% | โ27.3% | โ53.0% | โ84.5% | โ345.5% | 917.5% |
| Return on equity | โ | โ88.5% | โ1,143.7% | โ81.6% | โ99.7% | โ47.9% | โ43.3% | โ59.6% | โ134.5% | โ1,625.1% |
| Return on assets | โ825.0% | โ81.3% | โ482.5% | โ63.1% | โ85.7% | โ45.6% | โ41.4% | โ55.5% | โ110.8% | โ343.5% |
| Return on tangible equity | โ | โ43.1% | โ | โ63.5% | โ253.5% | โ29.6% | โ58.1% | โ95.6% | โ1,201.2% | โ |
| Growth | ||||||||||
| Share count change | โ | โ74.8% | โ33.7% | 70.1% | 170,562.8% | โ99.5% | โ | โ | โ81.9% | 91.6% |
| Financial health | ||||||||||
| Interest coverage | โ | โ110.9x | โ | โ | โ | โ | โ2,057.4x | โ | โ | โ58.8x |
| Current ratio | 0.2x | 19.5x | 0.7x | 4.3x | 4.7x | 24.0x | 18.4x | 8.5x | 1.4x | 0.2x |
| Quick ratio | 0.2x | 19.5x | 0.7x | 4.3x | 4.7x | 24.0x | 18.4x | 8.5x | 1.4x | 0.2x |
| Quality scores | ||||||||||
| Altman Z'' | โ135.9 | 21.2 | โ63.8 | 3.3 | โ3.4 | 27.6 | 17.2 | โ0.8 | โ46.5 | โ108.9 |
| Accruals ratio | โ311.1% | โ6.3% | โ151.0% | 18.0% | โ5.7% | โ7.9% | โ8.5% | โ6.5% | โ16.6% | โ116.3% |
Source: SEC EDGAR XBRL filings (CIK 0001621221). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ not investment advice. Check the original filings before relying on any figure.